Stock comparison
IDEXX Laboratories
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.76B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 68B | IDXX |
| Benjamin Graham | 80A | 78B | IDXX |
| Philip Fisher | 75B | 80A | NBIX |
| Peter Lynch | 71B | 65B | IDXX |
| Joel Greenblatt | 83C | 55C | IDXX |
| Charlie Munger | 87A | 60C | IDXX |
| Terry Smith | 84A | 63D | IDXX |
Side-by-side metrics
| Metric | IDXX | NBIX |
|---|---|---|
| Market cap | $44.06B | $15.76B |
| P/E (TTM) | 39.0x | 22.6x |
| EV/EBIT | 31.6x | 24.7x |
| ROIC (TTM) | 40.66% | 13.68% |
| Gross margin | 62.05% | 98.17% |
| Net margin | 24.63% | 21.55% |
| Revenue CAGR 5y | 7.56% | 26.04% |
| EPS CAGR 5y | 10.79% | 50.0% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 13.68%+66%
- Market cap$44.06Bvs $15.76B+64%
- Net margin24.63%vs 21.55%+13%
NBIX leads on
- Debt / Equity0.1xvs 0.7x+83%
- EPS CAGR 5y50.0%vs 10.79%+78%
- Revenue CAGR 5y26.04%vs 7.56%+71%
- P/E (TTM)22.6xvs 39.0x+42%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.